Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis. Our proprietary pan-amyloid removal (PAR) therapeutics are designed to directly bind to and remove toxic amyloid in organs and tissues. By targeting the universal disease-causing pathology in all systemic amyloidosis diseases, PAR therapeutics have the potential to treat and reverse disease in patients with all types and stages of systemic amyloidosis.
| Website | https://www.attralus.com/ |
| Employees | 27 (27 on RocketReach) |
| Industry | Biotechnology Research |
| Keywords | Clinical Stage Drug Development, Biopharmaceutical Research, Pharmaceutical Development, Novel Therapeutics, Drug Discovery Platform, Targeted Therapies, Translational Research, Clinical Trials, Precision Medicine, Drug Candidates, Protein Aggregation, Biotechnology, New Drug Applications, Therapeutic Antibodies |
| Competitors | Pfizer, Amgen, Bristol Myers Squibb, AstraZeneca, AbbVie, Genentech, Sanofi, Regeneron, GSK, Lilly India +37 more (view full list) |
Looking for a particular Attralus employee's phone or email?
Attralus Questions
Spencer Guthrie is the CEO of Attralus.
27 people are employed at Attralus.
Attralus is based in Naples, Florida.
Top Attralus Employees
-
Spencer Guthrie
Chief Executive Officer at Attralus
San Francisco, CA, US45+ -
35
-
Glen Firestone
President at Attralus
Philadelphia, PA, US25 -
Gregory Bell
Chief Medical Officer at Attralus
Tiburon, CA, US25 -
32
-
Christine Huh
Head of Human Resources at Attralus
United States25+ -
James Testa
Vice President Finance at Attralus
Mahwah, NJ, US31
Related Companies
